Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection
Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.
